Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular degeneration.
Doug Love, Annexon’s chief executive officer and president, said the company views vonaprument as differentiated from currently approved geographic atrophy therapies because it is designed as a neuroprotective approach aimed at preserving vision rather than targeting lesion growth alone. He said the drug is a small antibody Fab fragment with low viscosity and a 25-microliter injection volume, which he contrasted with larger-volume approved therapies.
